{
    "organizations": [],
    "uuid": "2ebb99ede7f6695b6dc8b3fde8daa9640c582ad9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-hybrigenics-fy-operating-loss-wide/brief-hybrigenics-fy-operating-loss-widens-to-7-4-million-euros-presents-update-on-inecalcitol-clinical-studies-idUSFWN1S31Q4",
    "ord_in_thread": 0,
    "title": "Hybrigenics FY Operating Loss Widens To 7.4 Million Euros, Presents Update On Inecalcitol Clinical Studies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 26 (Reuters) - HYBRIGENICS SA:\n* FY REVENUE EUR 0 MILLION VERSUS EUR 1.5 MILLION (RESTATED) YEAR AGO\n* FY OPERATING LOSS EUR 7.4 MILLION VERSUS LOSS OF EUR 4.0 MILLION (RESTATED) YEAR AGO\n* FY NET LOSS EUR 8.0 MILLION VERSUS LOSS OF EUR 5.3 MILLION (RESTATED) YEAR AGO\n* END-DEC CASH POSITION OF CONTINUED ACTIVITIES EUR 7.0 MILLION VERSUS EUR 8.5 MILLION (RESTATED) YEAR AGO\n* 87 PATIENTS RECRUITED IN INECALCITOL PHASE II ACUTE MYELOID LEUKEMIA STUDY\n* PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL SHOWS ABILITY TO DECREASE RESIDUAL CML DISEASE\n* PHASE II CHRONIC MYELOID LEUKEMIA STUDY: INECALCITOL EFFECTS BEYOND USUAL EFFECTS OF IMATINIB\n* DECISION ON LAUNCH OF NEXT CLINICAL TRIAL OF INECALCITOL IN CML TO BE MADE AFTER AML STUDY RESULTS\n* PHASE II AML INECALCITOL STUDY: TO ENROL 110 PATIENTS BEFORE END-2018, FINAL RESULTS EXPECTED IN 2019 Source text: bit.ly/2HAcCss (Gdynia Newsroom)\n ",
    "published": "2018-04-27T03:21:00.000+03:00",
    "crawled": "2018-04-27T17:06:56.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "hybrigenics",
        "sa",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "restated",
        "year",
        "ago",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "restated",
        "year",
        "ago",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "restated",
        "year",
        "ago",
        "cash",
        "position",
        "continued",
        "activity",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "restated",
        "year",
        "ago",
        "patient",
        "recruited",
        "inecalcitol",
        "phase",
        "ii",
        "acute",
        "myeloid",
        "leukemia",
        "study",
        "phase",
        "ii",
        "chronic",
        "myeloid",
        "leukemia",
        "study",
        "inecalcitol",
        "show",
        "ability",
        "decrease",
        "residual",
        "cml",
        "disease",
        "phase",
        "ii",
        "chronic",
        "myeloid",
        "leukemia",
        "study",
        "inecalcitol",
        "effect",
        "beyond",
        "usual",
        "effect",
        "imatinib",
        "decision",
        "launch",
        "next",
        "clinical",
        "trial",
        "inecalcitol",
        "cml",
        "made",
        "aml",
        "study",
        "result",
        "phase",
        "ii",
        "aml",
        "inecalcitol",
        "study",
        "enrol",
        "patient",
        "final",
        "result",
        "expected",
        "source",
        "text",
        "gdynia",
        "newsroom"
    ]
}